GlassScriptPhysician profile
Vladimir Ayvazyan
NPI 1477887206
$2,294.09
in general payments reported to CMS, 2019-2025
19 companies · $847 in 2025
The $847 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $176 · 2023: $640 · 2024: $631 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,117.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.71 | 2022-2025 | Stiolto Respimat, Jardiance, Spiriva Respimat |
| Abbvie INC. | $308.28 | 2023-2025 | Qulipta |
| Amgen INC. | $250.28 | 2023-2024 | Repatha, Otezla |
| Sumitomo Pharma America, INC. | $193.77 | 2024-2025 | Gemtesa |
| Inari Medical, INC. | $189.75 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ardelyx, INC. | $131.17 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $121.82 | 2025 | Yeztugo |
| Glaxosmithkline, LLC. | $106.62 | 2024-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $96.23 | 2022-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $81.86 | 2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $69.17 | 2023-2025 | Linzess |
| Lundbeck LLC | $47.78 | 2025 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.18 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $38.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $29.55 | 2025 | Farxiga |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $26.60 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $26.24 | 2025 | Dupixent |
| Corium, LLC | $21.59 | 2023 | Adlarity |
| Sunovion Pharmaceuticals INC. | $19.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vladimir Ayvazyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.